Tumor markers for bladder cancer: outlook for routine use

被引:0
作者
Ecke, Thorsten H. [1 ]
机构
[1] HELIOS Klinikum Bad Saarow, Urol Klin, D-15526 Bad Saarow Pieskow, Germany
来源
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE | 2010年 / 34卷 / 02期
关键词
bladder cancer; tumor marker; urothelial cell carcinoma; TRANSITIONAL-CELL CARCINOMA; TISSUE POLYPEPTIDE ANTIGEN; IN-SITU HYBRIDIZATION; GROWTH-FACTOR RECEPTOR-3; CARE PROTEOMIC ASSAY; TP53; GENE-MUTATIONS; URINARY-BLADDER; FOLLOW-UP; CLINICAL-IMPLICATIONS; UROTHELIAL CARCINOMA;
D O I
10.1515/JLM.2010.021
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
This article outlines the role of bladder cancer tumor markers in diagnosis and therapy with a particular focus on the most important biomarkers. A MEDLINE based literature search was performed to examine the field of bladder cancer markers. Further determination of recurrence and progression markers will contribute to establish better treatments for the individual patient. Molecular staging of urological tumors will allow selecting cases that will require systemic treatment. Therapeutically, knowledge of cancer progression pathways allows for drug therapies against specific tumor targets. It is necessary and important to integrate under the same objectives basic translational and clinical research.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 94 条
  • [1] Considerations on the use of diagnostic markers in management of patients with bladder cancer
    Agarwal, Piyush K.
    Black, Peter C.
    Kamat, Ashish M.
    [J]. WORLD JOURNAL OF UROLOGY, 2008, 26 (01) : 39 - 44
  • [2] Identification of PMF1 Methylation in Association with Bladder Cancer Progression
    Aleman, Ainel
    Cebrian, Virginia
    Alvarez, Miguel
    Lopez, Virginia
    Orenes, Esteban
    Lopez-Serra, Lidia
    Algaba, Ferran
    Bellmunt, Joaquin
    Lopez-Beltran, Antonio
    Gonzalez-Peramato, Pilar
    Cordon-Cardo, Carlos
    Garcia, Javier
    Garcia del Muro, Javier
    Esteller, Mane
    Sanchez-Carbayo, Marta
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (24) : 8236 - 8243
  • [3] Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer
    Als, Anne B.
    Dyrskjot, Lars
    von der Maase, Hans
    Koed, Karen
    Mansilla, Francisco
    Toldbod, Helle E.
    Jensen, Jens L.
    Ulhoi, Benedicte P.
    Sengelov, Lisa
    Jensen, Klaus M. E.
    Orntoft, Torben F.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4407 - 4414
  • [4] ANTIGENICITY OF POOLED HUMAN MALIGNANT AND NORMAL TISSUES BY CYTO-IMMUNOLOGICAL TECHNIQUE - PRESENCE OF AN INSOLUBLE, HEAT-LABILE TUMOR ANTIGEN
    BJORKLUND, B
    BJORKLUND, V
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1957, 10 (03): : 153 - 184
  • [5] BJORKLUND B, 1980, TUMORDIAGNOSTIK, V1, P9
  • [6] Quantitative molecular urinary cytology by fluorescence in situ hybridization:: a tool for tailoring surveillance of patients wit superficial bladder cancer?
    Bollmann, V
    Heller, H
    Bánkfalvi, A
    Griefingholt, H
    Bollmann, R
    [J]. BJU INTERNATIONAL, 2005, 95 (09) : 1219 - 1225
  • [7] The health economics of bladder cancer - A comprehensive review of the published literature
    Botteman, MF
    Pashos, CL
    Redaelli, A
    Laskin, B
    Hauser, R
    [J]. PHARMACOECONOMICS, 2003, 21 (18) : 1315 - 1330
  • [8] A COMMUNITY STUDY OF BLADDER-CANCER SCREENING BY THE DETECTION OF OCCULT URINARY BLEEDING
    BRITTON, JP
    DOWELL, AC
    WHELAN, P
    HARRIS, CM
    [J]. JOURNAL OF UROLOGY, 1992, 148 (03) : 788 - 790
  • [9] URINARY LEVELS OF TUMOR-ASSOCIATED ANTIGENS (CA-19-9, TPA AND CEA) IN PATIENTS WITH NEOPLASTIC AND NONNEOPLASTIC UROTHELIAL ABNORMALITIES
    CASETTA, G
    PIANA, P
    CAVALLINI, A
    VOTTERO, M
    TIZZANI, A
    [J]. BRITISH JOURNAL OF UROLOGY, 1993, 72 (01): : 60 - 64
  • [10] Dabrowski A, 2004, FOLIA HISTOCHEM CYTO, V42, P169